Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
about
The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort studyThe role of toxicity-related regimen changes in the development of antiretroviral resistanceHIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovirTreatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western KenyaAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk.2014 Update of the drug resistance mutations in HIV-1Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapyDecreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.Cohort profile: the Swiss HIV Cohort study.An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.Discovery and Development of Tenofovir Disoproxil Fumarate
P2860
Q33681279-D980C7BA-5B39-4554-9EF6-31AF14B01A1FQ34292138-BB43F053-ACCF-4354-9733-7D5765A3FEF4Q35330053-1A6A21C7-72F6-4DC0-8532-3C91D6F9E114Q36558495-0AE6D63E-B934-49F8-87FE-67F1B5180602Q36940983-89B3C8E2-424C-427F-9776-CC2FED1C3C3BQ37189622-99CD370E-EB2E-4B6D-AB11-B954C10EA6D3Q37942538-928C46D3-A986-47E5-B17E-0FC09430F2CEQ38898319-7757FCFA-5532-4519-BA8F-81AA86B5FBA0Q39498339-E42419F4-C208-4BEE-9F0F-744DB6A17F2AQ42430831-712F686A-B05F-4201-97B3-C8238059AD59Q42704290-2B06F73E-FA92-4A62-A572-FF31E4F909ECQ46959264-D462FC18-1AB3-4FD7-9B00-EEFE1B2C139BQ55340159-F10FCC86-7D64-4F39-BA9F-50795AC1B593Q56786248-C38D7A4B-83D6-4670-BF6E-9151C5B53087
P2860
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Factors associated with the em ...... therapy containing tenofovir.
@en
Factors associated with the em ...... therapy containing tenofovir.
@nl
type
label
Factors associated with the em ...... therapy containing tenofovir.
@en
Factors associated with the em ...... therapy containing tenofovir.
@nl
prefLabel
Factors associated with the em ...... therapy containing tenofovir.
@en
Factors associated with the em ...... therapy containing tenofovir.
@nl
P2093
P2860
P50
P356
P1476
Factors associated with the em ...... therapy containing tenofovir.
@en
P2093
Bruno Ledergerber
Martin Rickenbach
Philippe Bürgisser
Pietro L Vernazza
P2860
P304
P356
10.1086/528863
P407
P50
P577
2008-04-01T00:00:00Z